Financials in USD. Standardized financial statements.
A compact view of how Pluristem Therapeutics Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $1.34M | $0 | $23,000 | $54,000 | $50,000 | $0 | $2.85M | $379,000 | $379,000 | $679,000 |
| Revenue Growth? | 0.0% | -100.0% | -57.4% | +8.0% | 0.0% | -100.0% | +651.2% | 0.0% | -44.2% | 0.0% |
| Cost of Revenue? | $682,000 | $0 | $0 | $2,000 | $2,000 | $0 | $100,000 | $13,000 | $11,000 | $20,000 |
| Gross Profit? | $654,000 | $0 | $23,000 | $52,000 | $48,000 | $0 | $2.75M | $366,000 | $368,000 | $659,000 |
| Gross Margin? | +49.0% | 0.0% | +100.0% | +96.3% | +96.0% | 0.0% | +96.5% | +96.6% | +97.1% | +97.1% |
| Operating Expenses? | $23.98M | $50.62M | $29.50M | $35.58M | $33.78M | $28.02M | $26.07M | $25.63M | $28.22M | $22.88M |
| Operating Income? | -$23.33M | -$50.62M | -$29.48M | -$35.53M | -$33.73M | -$28.02M | -$23.32M | -$25.27M | -$27.85M | -$22.22M |
| EBITDA? | -$23.33M | -$48.42M | -$27.39M | -$33.57M | -$24.11M | -$25.64M | -$21.10M | -$22.60M | -$25.03M | -$20.09M |
| Income Before Tax | -$23.25M | -$49.87M | -$29.15M | -$35.31M | -$26.13M | -$27.81M | -$23.25M | -$24.68M | -$26.93M | -$21.16M |
| Income Tax Expense | $0 | $0 | $0 | $225,000 | $0 | $205,000 | $73,000 | $0 | $0 | $0 |
| Net Income? | -$23.25M | -$49.87M | -$29.15M | -$35.31M | -$26.13M | -$27.81M | -$23.25M | -$24.68M | -$26.93M | -$21.16M |
| EPS? | $-3.56 | $-1.77 | $-1.60 | $-2.86 | $-2.47 | $-3.18 | $-2.92 | $-3.51 | $-4.24 | $-3.81 |
| Diluted EPS? | $-3.56 | $-1.77 | $-1.60 | $-2.86 | $-2.47 | $-3.18 | $-2.92 | $-3.51 | $-4.24 | $-3.81 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality